Rubius Therapeutics, Inc
RUBY
RUBY was delisted on the 6th of March, 2023.
84 hedge funds and large institutions have $382M invested in Rubius Therapeutics, Inc in 2020 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 24 increasing their positions, 32 reducing their positions, and 13 closing their positions.
2% less funds holding
Funds holding: 86 → 84 (-2)
15% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 13
17% less capital invested
Capital invested by funds: $462M → $382M (-$79.9M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
25% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 32
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$1.33M |
| 2 |
Renaissance Technologies
New York
|
+$579K |
| 3 |
Millennium Management
New York
|
+$387K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$263K |
| 5 |
HF
HRT Financial
New York
|
+$244K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.18M |
| 2 |
MA
MYDA Advisors
Woodmere,
New York
|
-$1.76M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.14M |
| 4 |
Morgan Stanley
New York
|
-$1.03M |
| 5 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$933K |
RUBY Hedge Fund Activity: Q3 2020 in Review
84 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Rubius Therapeutics, Inc (RUBY) for Q3 2020, worth a combined $382M — down 17% from $462M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of RUBY and 11 opened new positions — a net loss of 2 holders — while 32 trimmed existing stakes and 24 added.
The largest buyer was JP Morgan Chase, adding an estimated $1.33M. The largest seller was Vanguard Group, cutting an estimated $4.18M.
- 84 institutional investors held Rubius Therapeutics, Inc (RUBY) as of Q3 2020, down from 86 in Q2 2020.
- Funds reported $382M of Rubius Therapeutics, Inc stock for Q3 2020, down 17% quarter-over-quarter.
- 11 funds opened new Rubius Therapeutics, Inc positions in Q3 2020 and 13 closed out, a net change of -2 holders.
- The largest Rubius Therapeutics, Inc buyer in Q3 2020 was JP Morgan Chase, an estimated $1.33M added.
- The largest Rubius Therapeutics, Inc seller in Q3 2020 was Vanguard Group, an estimated $4.18M sold.
Based on aggregated 13F filings for Q3 2020.